EDAP Reports 69% Growth in HIFU Revenues and Operating

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EDAP Reports 69% Growth in HIFU Revenues and Operating Profit for First Half 2016
  • Total EDAP revenue up 20.4% year-over-year in the first six months of 2016
  • Continued growth in HIFU system sales and treatment-driven revenue with strong margins
  • Focal One® 510k under FDA review
  • Solid cash position at €21.9 million as of June 30, 2016

LYON, France, Aug. 25, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq: EDAP ), the global leader in therapeutic ultrasound, announced today financial results for the second quarter and six months ended June 30, 2016, and provided an update on strategic and operational accomplishments. 

Marc Oczachowski, EDAP’s Chief Executive Officer, stated, “EDAP has made steady progress in the first half of the year. The FDA clearance of Ablatherm Robotic HIFU in late 2015 has resulted in strong system sales, while the growth in treatment driven revenues continued as a result of the traction and momentum of HIFU globally.”

“The solid performance of the HIFU division, in which revenues increased 69% over the first half of 2015, is clear evidence that our market penetration strategy is working and supports the expansion and growth of our global HIFU business. We continue penetrating the U.S. market with our strategy of targeting large and recognized institutions directly, while also providing access to the entire urology community by partnering with mobilizers and service providers.

In April, we submitted a 510(k) application for our next generation Focal One® HIFU system with the FDA. We are closely working on the file through direct interaction with the agency.” 

Mr. Oczachowski added, “We are pleased with our business development during the first half of 2016, and with the great traction we are achieving in our HIFU division with a significant increase in our project pipeline, particularly in the U.S. Thanks to this continued growth, the company generated an operating profit for the first half of the year and has a solid cash position that makes EDAP well-funded to further drive its growth and expansion initiatives.”

Second Quarter 2016 Results

Total revenue for the second quarter 2016 was EUR 8.2 million (USD 9.2 million), a 4.6% year-over-year increase compared to EUR 7.8 million (USD 8.7 million) for the second quarter 2015.

Total revenue in the HIFU business for this quarter was EUR 3.4 million (USD 3.8 million) compared to EUR 2.3 million (USD 2.6 million) for the second quarter 2015. HIFU revenue included the sale of three Ablatherm systems and one Focal One.

For the three months ended June 30, 2016, total revenue for the Lithotripsy division was EUR 4.8 million (USD 5.4 million), compared to EUR 5.5 million (USD 6.1 million), during the year ago period.

Gross profit for the second quarter 2016 was EUR 3.5 million (USD 3.9 million), compared to EUR 3.3 million (USD 3.7 million) for the year ago period. Gross profit margin on net sales was 42.3% in the second quarter of 2016, compared to 42.5% in the year ago period.

Operating expenses were EUR 3.8 million (USD 4.3 million) for the second quarter 2016, compared to EUR 3.6 million (USD 3.9 million) for the same period in 2015.

Operating loss for the second quarter 2016 was EUR 0.3 million (USD 0.4 million), compared with EUR 0.2 million (USD 0.2 million) in the second quarter of 2015.

Net income for the second quarter 2016 was EUR 2.5 million (USD 2.8 million), or EUR 0.08 per diluted share, as compared to net income of EUR 0.5 million (USD 0.5 million), or EUR 0.02 per diluted share, in the year ago period. Net income in the second quarter of 2016 included non-cash interest income of EUR 2.4 million to adjust the accounting fair value of the outstanding warrants.

First Six Months 2016 Results

Total revenue for the first half of 2016 was EUR 16.9 million (USD 18.9 million), up 20.4% compared to EUR 14.1 million (USD 15.6 million) for the first half of 2015.

Total revenue in the HIFU division for the first six months 2016 was EUR 6.7 million (USD 7.4 million) compared to EUR 3.9 million (USD 4.4 million) for the six months ended June 30, 2015. HIFU revenue included the sale of six Ablatherm systems and two Focal One.

For the six months ended June 30, 2016, total revenue for the Lithotripsy division was EUR 10.2 million (USD 11.4 million), compared to EUR 10.1 million (USD 11.2 million), during the year ago period. 

Gross profit for the first half of 2016 was EUR 7.8 million (USD 8.6 million) and gross profit margin was 45.8%, compared to 42.1% in the year ago period.

Operating expenses were EUR 7.4 million (USD 8.2 million) for the first six months of 2016, compared to EUR 6.8 million (USD 7.5 million) for the same period in 2015.

The Company recorded an operating profit the first half of 2016 of EUR 0.4 million (USD 0.4 million), compared with an operating loss of EUR 0.8 million (USD 0.9 million) in the first six months of 2015.

Net income for the first half of 2016 was EUR 3.9 million (USD 4.3 million), or EUR 0.13 per diluted share, as compared to a net loss of EUR 2.0 million (USD 2.2 million), or EUR 0.08 per diluted share, in the first half of 2015. Net income in the first half of 2016 included a non-cash interest income of EUR 2.9 million to adjust the accounting fair value of the outstanding warrants.

At June 30, 2016, cash and cash equivalents, including short-term treasury investments, were EUR 21.9 million (USD 24.2 million).

Conference Call EDAP will hold a conference call on Thursday, August 25 th , 2016 at 8:30 a.m. EDT to discuss the results and provide an update on recent business developments. The dial-in numbers are 1-888-348-6419 in the U.S., and 1-412-902-4235 for international callers.  The conference ID number for both is 10091258. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.edap-tms.com .

After the live event, the webcast will remain available on EDAP’s website, www.edap-tms.com , through September 27, 2016.  In addition, a dial-in replay of the call will be available.  The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers.  Please use event passcode 10091258.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit  http://www.edap-tms.com , and  http://www.hifu-planet.com .

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

EDAP TMS S.A.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)  
(Amounts in thousands of Euros and U.S. Dollars, except per share data)  
 
  Three Months Ended:       Three Months Ended:  
    June 30,       June 30,       June 30,       June 30,    
    2016     2015     2016     2015  
    Euros     Euros     $US     $US  
Sales of goods   5,262     5,357     5,896     5,948  
Net Sales of RPP and Leases   1,316     1,090     1,474     1,210  
Sales of spare parts and                        
Services    1,611     1,388     1,805     1,541  
TOTAL NET SALES   8,189     7,834     9,174     8,699  
Other revenues   8     2     9     2  
TOTAL REVENUES   8,197     7,836     9,183     8,701  
Cost of goods   (2,768 )    (2,996 )    (3,101 )   (3,327 ) 
Cost of RPP and Leases   (805 )    (648 )    (902 )    (720 ) 
Cost of spare parts & services   (1,162 )    (861 )    (1,302 )    (956 ) 
Cost of sales   (4,736 )    (4,505 )    (5,305 )    (5,002 ) 
                         
GROSS PROFIT   3,461     3,331     3,878     3,699  
Research & development expenses   (887 )    (739 )    (993 )    (820 ) 
Marketing & Sales expenses    (2,147 )    (1,859 )    (2,406 )    (2,064 ) 
G & A expenses    (772 )    (950 )    (865 )    (1,055 ) 
Total operating expenses   (3,806 )    (3,548 )    (4,264 )    (3,940 ) 
                         
OPERATING PROFIT (LOSS)   (345 )    (217 )    (386 )    (241 ) 
Interest (expense) income, net   2,412     1,005     2,702     1,116  
Currency exchange gains (loss), net   483     (262 )    541     (291 ) 
Other income (loss), net   -     -     -     -  
                         
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST   2,550     526     2,857     584  
Income tax (expense) credit   (52 )    (39 )    (58 )    (43 ) 
 
NET INCOME (LOSS)     2,498     487     2,799     541  
Earning per share – Basic   0.09     0.02     0.109     0.02  
                         
Average number of shares used in computation of Basic EPS   28,288,307     24,958,174     28,288,307     24,958,174  
                         
Earning per share – Diluted   0.08     0.02     0.09     0.02  
                         
Average number of shares used in computation of Diluted EPS   29,826,117     27,016,460     29,826,117     27,016,460  
                     
NOTE:   Translated for convenience of the reader to U.S. dollars at the 2016 average three months’ noon buying rate of 1 Euro = 1.1203 USD, and 2015 average three months’ noon buying rate of 1 Euro = 1.1104 USD.

 

EDAP TMS S.A.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)  
(Amounts in thousands of Euros and U.S. Dollars, except per share data)  
 
  Six Months Ended:     Six Months Ended:  
    June 30,       June 30,       June 30,       June 30,  
    2016     2015     2016     2015  
    Euros     Euros     $US     $US  
Sales of goods   11,261     9,103     12,518     10,095  
Net Sales of RPP and Leases   2,578     2,119     2,865   2,350
Sales of spare parts and                        
Services    3,078     2,830     3,421     3,138  
TOTAL NET SALES   16,917     14,052     18,805     15,584  
Other revenues   8     2     9     2  
TOTAL REVENUES   16,925     14,054     18,814     15,586  
Cost of goods   (5,561 )    (5,042 )    (6,182 )    (5,591 ) 
Cost of RPP and Leases   (1,513 )    (1,292 )    (1,681 )    (1,433 ) 
Cost of spare parts & services   (2,097 )    (1,809 )    (2,332 )    (2,006 ) 
Cost of sales   (9,171 )    (8,143 )    (10,195 )    (9,030 ) 
                         
GROSS PROFIT   7,753     5,911     8,619     6,556  
Research & development expenses   (1,701 )    (1,512 )    (1,890 )    (1,677 ) 
Marketing & Sales expenses    (4,013 )    (3,408 )    (4,460 )    (3,780 ) 
G & A expenses    (1,652 )    (1,830 )    (1,836 )    (2,030 ) 
Total operating expenses   (7,365 )    (6,750 )    (8,187 )    (7,486 ) 
                         
OPERATING PROFIT (LOSS)   388     (839 )    432     (931 ) 
Interest (expense) income, net   2,891     (1,344 )    3,213     (1,491 ) 
Currency exchange gains (loss), net   671     303     746     336  
Other income (loss), net   -     (3 )    -     (3 ) 
                         
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST   3,950     (1,884 )     4,391     (2,089 ) 
Income tax (expense) credit   (91 )    (69 )    (101 )    (77 )
 
NET INCOME (LOSS)     3,859     (1,953 )    4,289     (2,166 ) 
                         
Earning per share – Basic   0.14     (0.08 )    0.16     (0.09 ) 
                         
Average number of shares used in computation of Basic EPS   26,844,696     24,926,627     26,844,696     24,926,627  
                         
Earning per share – Diluted   0.13     (0.08 )    0.15     (0.09 ) 
                         
Average number of shares used in computation of Diluted EPS   28,615,172     24,926,627     28,615,172     24,926,627  
                         
NOTE:   Translated for convenience of the reader to U.S. dollars at the 2016 average six months’ noon buying rate of 1 Euro = 1.1116 USD, and 2015 average six months’ noon buying rate of 1 Euro = 1. 1090 USD.

 

EDAP TMS S.A.  
CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (Amounts in thousands of Euros and U.S. Dollars)  
 
    June 30,     Mar.   31,     June 30,     Mar.   31,    
    2016   2016   2016   2016  
    Euros   Euros   $US   $US  
 
Cash, cash equivalents and short term investments    21,940   14,533   24,203   16,552  
Total current assets   40,963   33,019   45,188   37,607  
Total current liabilities   14,817   16,529   16,345   18,826  
Shareholders’ Equity    24,358   15,901   26,870   18,111  
 
NOTE:  Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.1031 USD, on June 30, 2016 and at the noon buying rate of 1 Euro = 1.1390 USD, on March 31, 2016.  

 

EDAP TMS S.A.    
CONDENSED STATEMENTS OF OPERATIONS BY DIVISION  
SIX MONTHS ENDED JUNE 30, 2016  
(Amounts in thousands of Euros)  
                               
  HIFU Division     UDS Division   FDA Trials     Corporate       Total After Consolidation    
                                           
Sales of goods 4,536         6,725                     11,261        
Sales of RPPs & Leases 1,811         766                     2,578        
Sales of spare parts & services 328         2,750                     3,078        
TOTAL NET SALES 6,676         10,241                     16,917        
                                           
Other revenues 6         2                     8        
                                           
TOTAL REVENUES 6,682         10,243                     16,925        
                                           
GROSS PROFIT 4,081   61 %   3,672   36 %               7,753   46 %  
 (% of Total Revenues)                                          
                                           
Research & Development (1,048 )        (653 )      -             (1,701 )      
Total SG&A plus depreciation (1,979 )        (2,996 )            (689 )      (5,664 )      
                    -                      
OPERATING PROFIT (LOSS) 1,054         23             (689 )      388        
                                           

 

 

 

Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com Investors: Lee Roth The Ruth Group 646-536-7012 lroth@theruthgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 51

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 47

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
News Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles